RT Journal Article
SR Electronic
T1 Bayesian Network Modelling for the Clinical Diagnosis of Alzheimer’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.30.23300452
DO 10.1101/2023.12.30.23300452
A1 Bate St Cliere, Amber-Rose
A1 Fenton, Norman
YR 2024
UL http://medrxiv.org/content/early/2024/01/03/2023.12.30.23300452.abstract
AB Alzheimer’s disease (AD) is a progressively debilitating disease commonly affecting the elderly. Correct diagnosis is important for patients to access suitable therapies and support that can help improve or manage symptoms of the condition. Reports of misdiagnosis and difficulty diagnosing AD highlight existing clinical challenges. Here we propose a Bayesian network as a preliminary model for a complementary clinical diagnostic tool for dementia due to AD and mild cognitive impairment due to AD. The model structure was built based on medical reasoning patterns which help bridge the gap between clinical professionals and algorithmic decision making. The parameters of the model were specified from a combination of learning from data (using the NACC Uniform Data Set), extracting data from literature, and knowledge-based judgment. The resulting model includes variables laid out in NIA-AA diagnostic criteria and differentiates actual AD cases from formal AD diagnoses. The model is validated against a range of real-world data. Unlike machine-learnt (black box) AI models, this model provides a visible and auditable justification for its predictions and can be used for multiple types of ‘what if analysis’. An easy-to-use web accessible version of the model has been made available.Competing Interest StatementNorman Fenton is the Director of Agena. The remaining authors declare no competing interests.Funding StatementThe NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADCs: P50 AG005131 (PI James Brewer, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50 AG005138 (PI Mary Sano, PhD), P50 AG005142 (PI Helena Chui, MD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005681 (PI John Morris, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG008051 (PI Thomas Wisniewski, MD), P50 AG008702 (PI Scott Small, MD), P30 AG010124 (PI John Trojanowski, MD, PhD), P30 AG010129 (PI Charles DeCarli, MD), P30 AG010133 (PI Andrew Saykin, PsyD), P30 AG010161 (PI David Bennett, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG013854 (PI Robert Vassar, PhD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P30 AG019610 (PI Eric Reiman, MD), P50 AG023501 (PI Bruce Miller, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG028383 (PI Linda Van Eldik, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P30 AG035982 (PI Russell Swerdlow, MD), P50 AG047266 (PI Todd Golde, MD, PhD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG049638 (PI Suzanne Craft, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Marwan Sabbagh, MD), P20 AG068077 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Alzheimer's Coordinating Center (NACC) database is available to researchers upon request and a signed data use agreement. Written informed consent is obtained from all participants of ALzheimer's Disease Research Centers that contribute to the database.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData obtained from the National Alzheimer's Coordinating Center are available upon request online at https://naccdata.org/